Investing.comDoubao · 实盘可交易 · 做多市场:美股把握 5/10
北京时间·🕒 发布 21:36:32·⟳ 抓取 21:37:06 +34s·⚡ 决策 10-27 22:06:15 +29m09s·1.4 小时前
Oncolytics公布pelareorep肛管癌队列约15个月中位缓解持续时间
官方新闻稿在美股开盘时发布，方向明确且发布后约30分钟股价基本未反应；虽然证据仍属早期、小样本和跨试验比较，但对约6200万美元市值的临床期公司可能形成短线重估，适合试探仓而非正常仓位。
📄 原文Investing.com↗ 原文
Oncolytics reports 15-month response duration in anal cancer trial
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) announced today updated data from Cohort 4 of its Phase 1/2 GOBLET st…
⋯ 待结算 · 等待开盘离场入场 10-27 盘中首笔 @0.489 → 等下一常规开盘离场
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑做多：肛管癌耐久性数据新鲜，小盘临床股尚未反应
怎么买 立刻买入 不高于消息价 +3%
怎么卖 止盈 +5%(半仓)/+10%(清仓) · 止损 -7% · 时间止损 3日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 ONCY.US Oncolytics Biotech Inc.
10-27 盘中或未补齐(盘中约每 15 分钟更新) · 10-28、10-29 尚未交易 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时) · 10-27 仅常规时段(盘前盘后数据未就绪)
- 发布 10-27 21:36 北京(美东 10-27 09:36)
- 抓取 10-27 21:37 北京(美东 10-27 09:37)
- 入场 10-27 21:40 北京(美东 10-27 09:40) · 盘中首笔 @0.489
- 决策 10-27 22:06 北京(美东 10-27 10:06)
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做多 ONCY.US Oncolytics Biotech Inc.
| 收益状态 | 待结算 等待开盘离场 |
|---|---|
| 进场成交 | 2026-10-27 · 盘中首笔 · 10-27 21:40 北京 · @0.4889 · 成交 1% |
| 离场成交 | — |
| 建仓日 | 2026-10-27 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 23:17
研究档案
结论摘要
Oncolytics报告同一肛管癌联合方案更长的耐久性随访，约15个月DOR优于其引用的9.5个月对照，且OS尚未达到。数据不是注册性成功或合作落地，但公司市值小、消息新鲜且盘中尚未明显定价，值得小仓试探。
消息传播链
- 公司通过GlobeNewswire发布肛管癌GOBLET队列耐久性和生存数据，是本次催化的首发节点。市场反应:美东10:02 ONCY报0.4724美元，较前收约-0.17%，未见明显即时定价。
- Investing.com在首发后约6分钟发布AI辅助生成、编辑审核的公司新闻摘要，扩散范围仍有限。
关键理由
- 约15个月DOR、mOS未达到和多名24个月存活者强化pelareorep作为HPV相关肿瘤免疫骨架的平台预期。
- ONCY市值仅约6194万美元且新闻稿发布后股价约持平，历史同公司GOBLET读出首日多为正反应，存在短线预期差。
主要风险
- 这是Phase 1/2小样本随访和跨试验比较，未披露随机对照、置信区间或新的ORR，临床说服力有限。
- 股票20日下跌28.6%、日均成交额仅约70.8万美元，趋势弱且流动性差，可能无法持续重估。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-01-12 · 影响 weakens
同一队列数据已在2026年1月和2025年10月披露过，本次主要是随访延长；15个月与9.5个月对照属于跨试验比较，并非随机头对头证明。
检索:GOBLET Cohort 4 prior data January 2026 ORR DOR sample size cross-trial retifanlimab 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-10-27 · 影响 weakens
ONCY近20日下跌28.63%、距52周高点下跌64.15%，20日平均成交额约70.8万美元；弱势轨迹和低流动性削弱做多把握。
检索:ONCY recent stock trend 20 day decline liquidity market cap
先例如何影响了这次决策
对本次决策的影响:先例支持试探性做多和短持有期，但因盘中首发只有日线锚、样本质量thin且无clean high-grade样本，仓位降为probe，止盈集中在1至3个交易日。
方向:4条同公司GOBLET相关先例首日均上涨，中位首日收益约4.54%、首日胜率100%，但样本仅4条且置信区间很宽。
涨幅量级:高相似肛管癌更新首日分别约+0.83%和+2.47%，其他GOBLET更新为+6.61%和+9.84%；因此本次止盈第一档保守设为5%、第二档10%，不采用更高弹性。
形态:第3日中位仍为正，但第5日中位收益降至约2.02%且2025-10-28肛管癌更新第5日下跌9.92%，说明不宜长时间恋战。
历史先例(按相似度)
- 相似度 8/10 ONCY 2026-01-12 公司在盘中发布GOBLET Cohort 4更新，证明pelareorep联合atezolizumab在肛管癌中的活性。 原文 ↗
事件后 +1日 +2.5% · +2日 +3.3% · +3日 +8.5% · +4日 +0.6% · +5日 +4.4%
⚠来源层级不符(声明issuer/实为media)·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一GOBLET Cohort 4、同一pelareorep+atezolizumab肛管癌方案，均为更新数据。
经验:同一肛管癌队列更新曾带来首日+2.47%、第3日+8.50%的正向反应。 - 相似度 8/10 ONCY 2025-10-28 公司盘前报告pelareorep+atezolizumab的30% ORR，称超过现有标准治疗两倍。 原文 ↗
事件后 +1日 +0.8% · +2日 -3.3% · +3日 -4.1% · +4日 -1.6% · +5日 -9.9%
⚠来源层级不符(声明issuer/实为media)·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一肛管癌适应症和联合方案，且为ORR等关键疗效更新；但发布相位为盘前。
经验:重复的同一队列疗效更新首日反应很小且第5日回落，提示随访更新的持续性有限。 - 相似度 7/10 ONCY 2026-05-04 公司发布GOBLET结直肠癌队列持久缓解数据，事件前5日股价已下跌约15.5%。 原文 ↗
事件后 +1日 +6.6% · +2日 +5.2% · +3日 +5.7% · +4日 +3.4% · +5日 +2.3%
⚠盘中首发但只有日线，混入首发前走势·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同一GOBLET平台和早期小样本耐久性读出，但适应症是RAS突变MSS结直肠癌而非肛管癌。
经验:小盘临床期公司的阳性耐久性数据可带来约6.6%的首日反应，但第5日超额收益接近消失。 - 相似度 6/10 ONCY 2026-10-14 公司发布GOBLET研究临床数据及PanCAN资助尾款更新，事件前股价处于明显下跌后。 原文 ↗
事件后 +1日 +9.8% · +2日 +11.8% · +3日 +1.6% · +4日 +1.3% · +5日 +1.8%
⚠盘中首发但只有日线，混入首发前走势·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一GOBLET平台和近期股价环境，但内容为胰腺癌队列及资助进展，不是当前肛管癌数据。
经验:严重下跌后的小市值ONCY对GOBLET相关更新可出现约10%的首日反弹，但后续动能很快衰减。
工具执行结果 · 成功 13 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 553 ms
{"result": "search_processed_events:agent query=`oncolytics biotech pelareorep goblet anal cancer 15 month duration response | oncolytics pelareorep checkpoint inhibitor registrational fast track | oncy cohort 4 atezolizumab squa`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.8/72 小时、6027 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 1,678 ms
豆包搜索结果（原始查询:Oncolytics Biotech GOBLET Cohort 4 pelareorep atezolizumab anal cancer 15 months press release October 27 2026；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 2,490 ms
{ - web_search 成功 doubao_search · 2,696 ms
豆包搜索结果（原始查询:Oncolytics Biotech ONCY pelareorep clinical data stock reaction GOBLET phase 1/2 update anal cancer；API SearchType:web） - web_search 成功 doubao_search · 2,074 ms
豆包搜索结果（原始查询:"15 months" "GOBLET" "anal cancer" Oncolytics 2026；API SearchType:web） - web_search 成功 doubao_search · 548 ms
web_search「site:ir.oncolyticsbiotech.com/press_releases "15 months" pelareorep anal」无结果。 - web_search 成功 doubao_search · 2,150 ms
豆包搜索结果（原始查询:Oncolytics October 27 2026 15-month duration response pelareorep；API SearchType:web） - web_search 成功 doubao_search · 6,037 ms
豆包搜索结果（原始查询:ONCY stock October 27 2026 Oncolytics 15 month response duration；API SearchType:web） - web_search 成功 doubao_search · 1,867 ms
豆包搜索结果（原始查询:"Oncolytics Biotech® Reports Strong Durability and Survival Data" ORR DOR patients Cohort 4；API SearchType:web） - web_search 成功 doubao_search · 927 ms
豆包搜索结果（原始查询:"October 27, 2026 09:30 ET" ONCY pelareorep "15 months"；API SearchType:web） - web_search 成功 doubao_search · 924 ms
web_search「site:sec.gov/Archives/edgar/data/1129928 2026 "Strong Durability" "Anal Cancer"」无结果。 - web_search 成功 doubao_search · 3,062 ms
豆包搜索结果（原始查询:Oncolytics Biotech press release January 12 2026 GOBLET Cohort 4 ORR DOR stock；API SearchType:web） - event_study 降级 stock_tools HTTP · 3,380 ms
2 precedent(s) rejected; 1 benchmark warning(s)
原文全文
展开原文 · 2,018 字
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) announced today updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep combined with atezolizumab in patients with second-line or later squamous cell anal cancer.
The median duration of response reached approximately 15 months, according to a press release statement. The company compared this to 9.5 months for FDA-approved retifanlimab monotherapy in a similar patient population. Median overall survival has not yet been reached in the study.
All patients who responded to treatment survived beyond 12 months, with multiple patients surviving over 24 months, the company stated. More than 90% of squamous cell anal cancer cases are associated with human papillomavirus.
The GOBLET study is a Phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The co-primary endpoints are objective response rate and/or disease control rate and safety.
Oncolytics has received Fast Track Designation from the FDA for the treatment. The company stated it plans to explore additional clinical studies with a potential checkpoint inhibitor partner to support registrational development in squamous cell anal cancer.
The company indicated it may expand into HPV-associated head and neck squamous cell carcinoma. HPV accounts for approximately 70% of oropharyngeal cancers in the United States. Pelareorep has not yet been evaluated in combination with a checkpoint inhibitor in head and neck cancer.
Pelareorep is an intravenously delivered investigational immunotherapy that has been administered to over 1,200 patients. The company has received Fast Track designation from the FDA for pelareorep in colorectal, anal, and pancreatic cancer.
Oncolytics is a clinical-stage biotechnology company developing pelareorep as an immunotherapeutic agent.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The median duration of response reached approximately 15 months, according to a press release statement. The company compared this to 9.5 months for FDA-approved retifanlimab monotherapy in a similar patient population. Median overall survival has not yet been reached in the study.
All patients who responded to treatment survived beyond 12 months, with multiple patients surviving over 24 months, the company stated. More than 90% of squamous cell anal cancer cases are associated with human papillomavirus.
The GOBLET study is a Phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The co-primary endpoints are objective response rate and/or disease control rate and safety.
Oncolytics has received Fast Track Designation from the FDA for the treatment. The company stated it plans to explore additional clinical studies with a potential checkpoint inhibitor partner to support registrational development in squamous cell anal cancer.
The company indicated it may expand into HPV-associated head and neck squamous cell carcinoma. HPV accounts for approximately 70% of oropharyngeal cancers in the United States. Pelareorep has not yet been evaluated in combination with a checkpoint inhibitor in head and neck cancer.
Pelareorep is an intravenously delivered investigational immunotherapy that has been administered to over 1,200 patients. The company has received Fast Track designation from the FDA for pelareorep in colorectal, anal, and pancreatic cancer.
Oncolytics is a clinical-stage biotechnology company developing pelareorep as an immunotherapeutic agent.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
858b0ecb94· 2026-10-27 22:06 · doubao / doubao-seed-evolving-latest-version · 策略包2cd9474a9f7b当前